4588 — Oncolys Biopharma Income Statement
0.000.00%
Last trade - 00:00
- ¥14bn
- ¥13bn
- ¥63m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,304 | 314 | 642 | 976 | 63 |
Cost of Revenue | |||||
Gross Profit | 1,191 | 236 | 199 | 338 | 30.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,185 | 2,357 | 2,208 | 2,185 | 2,015 |
Operating Profit | -881 | -2,042 | -1,565 | -1,209 | -1,952 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -909 | -2,091 | -1,612 | -1,146 | -1,936 |
Provision for Income Taxes | |||||
Net Income After Taxes | -912 | -2,095 | -1,615 | -1,149 | -1,939 |
Net Income Before Extraordinary Items | |||||
Net Income | -912 | -2,095 | -1,615 | -1,149 | -1,939 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -912 | -2,095 | -1,615 | -1,149 | -1,939 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -48.3 | -129 | -91.2 | -66.9 | -108 |
Dividends per Share |